Lobe Sciences: Strengthening Assets for Explosive Growth in the Psychedelics Sector

By Kirsteen Mackay


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Lobe Sciences Ltd (CSE:LOBE | OTCPink:GTSIF)

Psychedelics are in the spotlight this year, enjoying stimulation as they’re recognised for the good they can do in treating depression and other mental health troubles. In a world that’s increasingly processed, manufactured and engineered, natural products are sought after. Lobe Sciences Ltd (CSE: LOBE | OTC Pink: GTSIF) is a newly rebranded company investing in this area.

Leveraging Transformative Medicine to Improve and Enhance Mental Health

Traditional medicines are being shunned in favour of natural alternatives as it’s refreshing to absorb something pure. Psychedelics have a natural ability to ease the debilitating effects of depression and severe mental health conditions. Lobe Sciences is a research and development (R&D) company developing unique medicines and devices to treat mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) along with other mental health conditions.

Lobe is working alongside the medical community to give patients the best of both worlds. Through its extensive research, it’s focussing on the clinical development of devices and the use of psychedelic medicines to treat specific indications and brain traumas.

The company comprises a small team of pioneering scientists and engineers, who share the vision of developing alternative treatments to achieve better health and wellness. Together they are working on creating a portfolio of transformational intellectual property, which will support wellbeing and improve all-round mental health.  

Lobe Sciences has five provisional patents in place. It’s begun a pre-clinical study and is engineering the development of a drug delivery device for Psilocybin through its Nasal Mist Transducer. The team is on a mission to discover and advance the creation of transformative new medicines, compounds and devices for the benefit of all.

Rebranding for a New Beginning

Lobe Sciences is the newly launched rebrand of a strong team committed to leading in the therapeutics space. It is determined to become a leader in developing effective therapeutics and devices using psychedelic and other naturally occurring compounds.

With a pure focus on the transformational power of psychedelic medicines, Lobe is at the forefront of a mushrooming industry. It sees this rebrand as the perfect way to embrace its vision and capitalize on the growth in this sector. This will ultimately bring great advantage to both the team and shareholders alike.

Lobe Sciences Sells Cowlitz Cannabis Option

On Dec 1, Lobe Sciences announced a letter of intent for the sale of its Cowlitz Cannabis Option to Ionic Brands Corp. (CSE: IONC) for CAD$23,000,000. Ionic is a growing US cannabis company focused on premium cannabis products.

The sale, when it closes, allows Lobe to focus solely on its psychedelic vision. It will receive the CAD$23 million in Ionic shares, expected to be around 49% of Ionic’s estimated $47 million capitalization post-restructuring.

While Lobe was enjoying monthly revenues from licensing and leasing agreements with Cowlitz, the company would prefer to streamline its focus on its psychedelics business. It believes this decision is good for shareholders and the business alike. The two businesses are complementary to one another, but the deal allows the Lobe team to focus on their area of expertise and lean on the expertise of Ionic when it comes to further growth and expansion down the line.

Tom Baird, CEO of Lobe comments:

“The proposed transaction with Ionic is accretive to both parties, successfully meets our M&A initiatives and keeps Lobe active in the cannabis and overall transformation psychedelic medicine space. It provides Lobe with significant ownership and board presence in Ionic. With its already significant operations in Washington State and Oregon, we feel Ionic’s proposed product expansion initiatives together with the addition of the Cowlitz Assets can lead to aggressive growth.”

A Pioneer in Psychedelic Medicines

Lobe Sciences has two main areas of expertise; growing its intellectual property portfolio through its R&D in transformational medicine and capitalizing on merger and acquisition opportunities. This sale of Cowlitz, is the latest in a string of similar deals designed to improve shareholder returns.

Earlier this year the company purchased Eleusian Biosciences Corp. This strategic acquisition furnishes Lobe with a host of development opportunities focused on mental wellbeing and optimal brain health.

The company’s efforts are split between the development of psychedelic medicines and the creation of devices to deliver these life-changing compounds. It has begun a study treating mTBI (concussion) using psilocybin and N-Acetylcysteine in collaboration with a team of scientists at the prestigious University of Miami Miller School of Medicine.

Concussion is a much more common occurrence than previously believed. It also contributes to several negative health outcomes. The Centers for Disease Control (“CDC“) estimates there are over 230,000 hospitalizations due to concussion each year plus 3 million emergency room visits. It’s thought around 5.3 million Americans are suffering side effects from mTBI, which is a jaw dropping 53% increase from a decade ago. The World Health Organisation (WHO) has even called it a silent epidemic. Sadly, there are no proven treatments for this or PTSD, so it’s a worthy area to be occupied. Therefore, Lobe hopes the results of this study will lead to human clinical trials and eventually therapeutics, which will drastically change millions of lives for the better.


Paid Advertisement

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Lobe Science Ltd. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of eighty thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

Changes in Share Trading and Price

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

No Offer to Sell or Buy Securities

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

No Financial Advice

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

Forward Looking Statements

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

Indemnification/Release of Liability

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

Terms of Use and Disclaimer

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact ValueTheMarkets.com to discontinue receiving future communications.

Intellectual Property

All trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than Valuethemarkets.com.

Authors: ValueTheMarkets

Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production of this piece by the company or companies mentioned above.


In this article:

Author: Kirsteen Mackay

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Sign up for Investing Intel Newsletter